R&D channel feed

FDA with­draws two fi­nal guid­ances, pulls com­pli­ance dead­lines for bone al­lo­graft mak­ers

4 weeks ago
Pharma
FDA+

Feng Zhang’s pro­tein nanopar­ti­cle start­up Aera Ther­a­peu­tics turns to lipid nanopar­ti­cles to jump­start its pipeline

4 weeks ago
Cell/Gene Tx

Drug­mak­ers ex­ploit can­cer’s ‘lethal­i­ties’ to make next class of tar­get­ed ther­a­pies, with first re­sults for Wern­er drug

4 weeks ago

In­vestors un­veil plans for $1.3B can­cer hub in Lon­don sub­urbs

4 weeks ago
Manufacturing

Mod­er­na, fac­ing rev­enue miss­es and po­lit­i­cal head­winds, dis­ap­points Wall Street

4 weeks ago
Pharma

CROs raise the alarm as clients de­lay R&D plans over fund­ing, tar­iff wor­ries

4 weeks ago
Outsourcing

Mod­er­na ex­pands ef­fort to rein in costs in an ‘un­cer­tain en­vi­ron­ment’

4 weeks ago
Pharma

Sci­en­tists alarmed about fu­ture of can­cer re­search; TIG­IT, CAR-NK and more from #AACR25

4 weeks ago

Ar­tios drug ex­ploits ‘repli­ca­tion stress’ in can­cer, shrink­ing sub­set of tu­mors in ear­ly study

4 weeks ago
Startups

No­var­tis con­tin­ues earn­ings win­ning streak as it rais­es 2025 sales ex­pec­ta­tions

4 weeks ago
Pharma

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

4 weeks ago

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

4 weeks ago
Pharma

Keytru­da around head and neck can­cer surgery cuts chance of dis­ease com­ing back

4 weeks ago

Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

4 weeks ago

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

4 weeks ago

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

5 weeks ago
Pharma
FDA+

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

5 weeks ago
China

Hop­ing to turn CD47 around with Keytru­da com­bo, ALX On­col­o­gy re­ports two Phase 2 fail­ures

5 weeks ago

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

5 weeks ago
People
Cell/Gene Tx

Sanofi's Al­tuvi­i­io clos­ing in on block­buster sta­tus, Dupix­ent sales surge

Last month
Pharma

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

Last month

Ake­so re­ports an­oth­er Phase 3 win for PD-1xVEGF ap­proach in lung can­cer

Last month

Boehringer taps Dutch biotech for ALT pos­i­tive can­cer pact ex­ceed­ing $573M in biobucks

Last month
Deals

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

Last month
Pharma
First page Previous page 123456 Next page Last page
A service from the Financial Times